A panel of 19 international PAH experts clarified and combined guidelines from around the globe on the initiation of oral PPAs in the treatment of patients with PAH and WHO FC II or FC III symptoms.
The panel combined the best available scientific evidence with their expertise to identify and form a consensus on 13 patient profiles in which UPTRAVI® (selexipag) has shown to benefit treatment outcomes.
In the McLaughlin et al. Consensus Opinion, IPAH+ was defined as patients with idiopathic, heritable, repaired congenital heart defect, or drug- or toxin-induced PAH. The use of UPTRAVI® is not recommended for patients with WHO FC I or FC IV symptoms.
Adapted from McLaughlin VV et al. 20203
Details of the GRIPHON study, where the safety and efficacy of UPTRAVI® were investigated in a Phase 3 study to assess the long-term benefits for pulmonary arterial hypertension (PAH) patients.
Advice on how to manage your UPTRAVI® patients, including details on dosage and side effects.
Details from the 2022 ESC/ERS guidelines to help you achieve and/or maintain a low-risk status for your patients with PAH.
A list of useful links to management guidelines, scientific and patient associations, the full Summary of Product Characteristics for UPTRAVI® and the patient information leaflet.
BNP, B-type natriuretic peptide; CTD, connective tissue disease; ERS, European Respiratory Society; ESC, European Society of Cardiology; FC, functional class; IPAH, idiopathic pulmonary arterial hypertension; MRI, magnetic resonance imaging; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PAH, pulmonary arterial hypertension; PPA, prostacyclin pathway agent; RV, right ventricle; 6MWD, 6-minute walk distance; WHO, World Health Organization